Skip to main content
Top
Published in: Journal of Translational Medicine 1/2017

Open Access 01-12-2017 | Research

Epidermal growth factor receptor and epididymis invasion as prognostic biomarkers in clinical stage I testicular germ cell tumours

Authors: Miguel F. Sanmamed, E. Esteban, E. Uriol, R. Zarate, M. Capelan, C. Muriel, G. Crespo, J. P. Berros, P. Pardo-Coto, Q. Perez, C. Alvarez-Fernández, P. Jiménez Fonseca, M. Luque, A. Astudillo

Published in: Journal of Translational Medicine | Issue 1/2017

Login to get access

Abstract

Background

Inguinal orchiectomy is curative in 70–80% of clinical stage I testicular germ cell tumours (CS I TGCT). The identification of patients who are at low risk of relapse is critical to avoid unnecessary treatment. The aim of this study is to explore EGFR, hMLH-1/hMSH-2 and microsatellite instability (MSI) as potential prognostic factors of recurrence in CS I TGCT.

Methods

Fifty-six CS I TGCT patients who underwent inguinal orchiectomy were included in this study. We analysed the relationship between clinicopathological and molecular factors with survival. Analysis of hMLH1, hMSH2 and EGFR expression was carried out by immunohistochemistry. Methylation status of the hMLH1 promoter was determined by pyrosequencing analysis in selected cases. EGFR exons 19, 20, 21 were analysed by PCR labeled-fragments and MSI status was determined using standard Multiplex MSI assays.

Results

Classical pathological factors such as lymphovascular invasion, high percentage of embryonal carcinoma, rete testis invasion or tumour size ≥4 cm showed a significant relationship with a higher risk of relapse. Additionally, it was found that an epididymis invasion proved to be a significant independent poor prognostic factor of recurrence (p = 0.001). hMLH1 or hMSH2 expression showed no significant association with risk of relapse and no MSI was found. EGFR expression was observed in 30.4% of samples and its expression was associated with higher risk of relapse (HR 3.5; 95% CI 1.3–9.8; p = 0.016). None of the cases presented EGFR kinase domain mutations.

Conclusions

Epididymis invasion and EGFR expression, but not hMLH-1/hMSH-2 or MSI, could be potentially useful as new prognostic factors of recurrence for CS I TGCT.
Appendix
Available only for authorised users
Literature
1.
go back to reference Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J, Rosso S, Coebergh JWW, Comber H, et al. Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur J Cancer. 2013;49:1374–403.CrossRefPubMed Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J, Rosso S, Coebergh JWW, Comber H, et al. Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur J Cancer. 2013;49:1374–403.CrossRefPubMed
2.
go back to reference Peckham MJ, Barrett A, Husband JE, Hendry WF. Orchidectomy alone in testicular stage I non-seminomatous germ-cell tumours. Lancet. 1982;2:678–80.CrossRefPubMed Peckham MJ, Barrett A, Husband JE, Hendry WF. Orchidectomy alone in testicular stage I non-seminomatous germ-cell tumours. Lancet. 1982;2:678–80.CrossRefPubMed
3.
go back to reference Freedman LS, Parkinson MC, Jones WG, Oliver RT, Peckham MJ, Read G, et al. Histopathology in the prediction of relapse of patients with stage I testicular teratoma treated by orchidectomy alone. Lancet. 1987;2:294–8.CrossRefPubMed Freedman LS, Parkinson MC, Jones WG, Oliver RT, Peckham MJ, Read G, et al. Histopathology in the prediction of relapse of patients with stage I testicular teratoma treated by orchidectomy alone. Lancet. 1987;2:294–8.CrossRefPubMed
4.
go back to reference Read G, Stenning SP, Cullen MH, Parkinson MC, Horwich A, Kaye SB, et al. Medical Research Council prospective study of surveillance for stage I testicular teratoma. Medical Research Council Testicular Tumors Working Party. J Clin Oncol. 1992;10:1762–8.CrossRefPubMed Read G, Stenning SP, Cullen MH, Parkinson MC, Horwich A, Kaye SB, et al. Medical Research Council prospective study of surveillance for stage I testicular teratoma. Medical Research Council Testicular Tumors Working Party. J Clin Oncol. 1992;10:1762–8.CrossRefPubMed
5.
go back to reference Albers P, Siener R, Krege S, Schmelz H-U, Dieckmann K-P, Heidenreich A, et al. Randomized phase III trial comparing retroperitoneal lymph node dissection with one course of bleomycin and etoposide plus cisplatin chemotherapy in the adjuvant treatment of clinical stage I Nonseminomatous testicular germ cell tumors: AUO trial AH 01/94. J Clin Oncol. 2008;26:2966–72.CrossRefPubMed Albers P, Siener R, Krege S, Schmelz H-U, Dieckmann K-P, Heidenreich A, et al. Randomized phase III trial comparing retroperitoneal lymph node dissection with one course of bleomycin and etoposide plus cisplatin chemotherapy in the adjuvant treatment of clinical stage I Nonseminomatous testicular germ cell tumors: AUO trial AH 01/94. J Clin Oncol. 2008;26:2966–72.CrossRefPubMed
6.
go back to reference Warde P, Specht L, Horwich A, Oliver T, Panzarella T, Gospodarowicz M, et al. Prognostic factors for relapse in stage I seminoma managed by surveillance: a pooled analysis. J Clin Oncol. 2002;20:4448–52.CrossRefPubMed Warde P, Specht L, Horwich A, Oliver T, Panzarella T, Gospodarowicz M, et al. Prognostic factors for relapse in stage I seminoma managed by surveillance: a pooled analysis. J Clin Oncol. 2002;20:4448–52.CrossRefPubMed
7.
go back to reference Aparicio J, Germà JR, del Muro XG, Maroto P, Arranz JA, Sáenz A, et al. Risk-adapted management for patients with clinical stage I seminoma: the Second Spanish Germ Cell Cancer Cooperative Group study. J Clin Oncol. 2005;23:8717–23.CrossRefPubMed Aparicio J, Germà JR, del Muro XG, Maroto P, Arranz JA, Sáenz A, et al. Risk-adapted management for patients with clinical stage I seminoma: the Second Spanish Germ Cell Cancer Cooperative Group study. J Clin Oncol. 2005;23:8717–23.CrossRefPubMed
8.
go back to reference Tandstad T, Smaaland R, Solberg A, Bremnes RM, Langberg CW, Laurell A, et al. Management of seminomatous testicular cancer: a binational prospective population-based study from the Swedish norwegian testicular cancer study group. J Clin Oncol. 2011;29:719–25.CrossRefPubMed Tandstad T, Smaaland R, Solberg A, Bremnes RM, Langberg CW, Laurell A, et al. Management of seminomatous testicular cancer: a binational prospective population-based study from the Swedish norwegian testicular cancer study group. J Clin Oncol. 2011;29:719–25.CrossRefPubMed
9.
go back to reference Albers P, Siener R, Kliesch S, Weissbach L, Krege S, Sparwasser C, et al. Risk factors for relapse in clinical stage I nonseminomatous testicular germ cell tumors: results of the German Testicular Cancer Study Group Trial. J Clin Oncol. 2003;21:1505–12.CrossRefPubMed Albers P, Siener R, Kliesch S, Weissbach L, Krege S, Sparwasser C, et al. Risk factors for relapse in clinical stage I nonseminomatous testicular germ cell tumors: results of the German Testicular Cancer Study Group Trial. J Clin Oncol. 2003;21:1505–12.CrossRefPubMed
10.
11.
go back to reference Devouassoux-Shisheboran M, Mauduit C, Bouvier R, Berger F, Bouras M, Droz JP, et al. Expression of hMLH1 and hMSH2 and assessment of microsatellite instability in testicular and mediastinal germ cell tumours. Mol Hum Reprod. 2001;7:1099–105.CrossRefPubMed Devouassoux-Shisheboran M, Mauduit C, Bouvier R, Berger F, Bouras M, Droz JP, et al. Expression of hMLH1 and hMSH2 and assessment of microsatellite instability in testicular and mediastinal germ cell tumours. Mol Hum Reprod. 2001;7:1099–105.CrossRefPubMed
12.
go back to reference Mayer F, Gillis AJM, Dinjens W, Oosterhuis JW, Bokemeyer C, Looijenga LHJ. Microsatellite instability of germ cell tumors is associated with resistance to systemic treatment. Cancer Res. 2002;62:2758–60.PubMed Mayer F, Gillis AJM, Dinjens W, Oosterhuis JW, Bokemeyer C, Looijenga LHJ. Microsatellite instability of germ cell tumors is associated with resistance to systemic treatment. Cancer Res. 2002;62:2758–60.PubMed
13.
go back to reference Velasco A, Corvalan A, Wistuba II, Riquelme E, Chuaqui R, Majerson A, et al. Mismatch repair expression in testicular cancer predicts recurrence and survival. Int J Cancer. 2008;122:1774–7.CrossRefPubMed Velasco A, Corvalan A, Wistuba II, Riquelme E, Chuaqui R, Majerson A, et al. Mismatch repair expression in testicular cancer predicts recurrence and survival. Int J Cancer. 2008;122:1774–7.CrossRefPubMed
14.
go back to reference Honecker F, Wermann H, Mayer F, Gillis AJM, Stoop H, van Gurp RJLM, et al. Microsatellite instability, mismatch repair deficiency, and BRAF mutation in treatment-resistant germ cell tumors. J Clin Oncol. 2009;27:2129–36.CrossRefPubMed Honecker F, Wermann H, Mayer F, Gillis AJM, Stoop H, van Gurp RJLM, et al. Microsatellite instability, mismatch repair deficiency, and BRAF mutation in treatment-resistant germ cell tumors. J Clin Oncol. 2009;27:2129–36.CrossRefPubMed
15.
go back to reference Sharma SV, Bell DW, Settleman J, Haber DA. Epidermal growth factor receptor mutations in lung cancer. Nat Rev Cancer. 2007;7:169–81.CrossRefPubMed Sharma SV, Bell DW, Settleman J, Haber DA. Epidermal growth factor receptor mutations in lung cancer. Nat Rev Cancer. 2007;7:169–81.CrossRefPubMed
16.
go back to reference Nicholson RI, Gee JM, Harper ME. EGFR and cancer prognosis. Eur J Cancer. 2001;37(Suppl 4):S9–15.CrossRefPubMed Nicholson RI, Gee JM, Harper ME. EGFR and cancer prognosis. Eur J Cancer. 2001;37(Suppl 4):S9–15.CrossRefPubMed
17.
go back to reference Krause DS, Van Etten RA. Tyrosine kinases as targets for cancer therapy. N Engl J Med. 2005;353:172–87.CrossRefPubMed Krause DS, Van Etten RA. Tyrosine kinases as targets for cancer therapy. N Engl J Med. 2005;353:172–87.CrossRefPubMed
18.
go back to reference Moroni M, Veronese S, Schiavo R, Carminati O, Sorensen BS, Gambacorta M, et al. Epidermal growth factor receptor expression and activation in nonseminomatous germ cell tumors. Clin Cancer Res. 2001;7:2770–5.PubMed Moroni M, Veronese S, Schiavo R, Carminati O, Sorensen BS, Gambacorta M, et al. Epidermal growth factor receptor expression and activation in nonseminomatous germ cell tumors. Clin Cancer Res. 2001;7:2770–5.PubMed
19.
go back to reference Kollmannsberger C, Mayer F, Pressler H, Koch S, Kanz L, Oosterhuis JW, et al. Absence of c-KIT and members of the epidermal growth factor receptor family in refractory germ cell cancer. Cancer. 2002;95:301–8.CrossRefPubMed Kollmannsberger C, Mayer F, Pressler H, Koch S, Kanz L, Oosterhuis JW, et al. Absence of c-KIT and members of the epidermal growth factor receptor family in refractory germ cell cancer. Cancer. 2002;95:301–8.CrossRefPubMed
20.
go back to reference Hechelhammer L, Störkel S, Odermatt B, Heitz PU, Jochum W. Epidermal growth factor receptor is a marker for syncytiotrophoblastic cells in testicular germ cell tumors. Virchows Arch. 2003;443:28–31.CrossRefPubMed Hechelhammer L, Störkel S, Odermatt B, Heitz PU, Jochum W. Epidermal growth factor receptor is a marker for syncytiotrophoblastic cells in testicular germ cell tumors. Virchows Arch. 2003;443:28–31.CrossRefPubMed
21.
go back to reference Madani A, Kemmer K, Sweeney C, Corless C, Ulbright T, Heinrich M, et al. Expression of KIT and epidermal growth factor receptor in chemotherapy refractory non-seminomatous germ-cell tumors. Ann Oncol. 2003;14:873–80.CrossRefPubMed Madani A, Kemmer K, Sweeney C, Corless C, Ulbright T, Heinrich M, et al. Expression of KIT and epidermal growth factor receptor in chemotherapy refractory non-seminomatous germ-cell tumors. Ann Oncol. 2003;14:873–80.CrossRefPubMed
22.
go back to reference Wang X, Zhang S, Maclennan GT, Biermann K, Foster RS, Beck SD, et al. Epidermal growth factor receptor protein expression and gene amplification in the chemorefractory metastatic embryonal carcinoma. Mod Pathol. 2009;22:7–12.CrossRefPubMed Wang X, Zhang S, Maclennan GT, Biermann K, Foster RS, Beck SD, et al. Epidermal growth factor receptor protein expression and gene amplification in the chemorefractory metastatic embryonal carcinoma. Mod Pathol. 2009;22:7–12.CrossRefPubMed
23.
go back to reference Durán I, García-Velasco A, Ballestín C, García E, Martínez-Tello F, Pond GR, et al. Expression of EGFR, HER-2/neu and KIT in germ cell tumours. Clin Transl Oncol. 2010;12:443–9.CrossRefPubMed Durán I, García-Velasco A, Ballestín C, García E, Martínez-Tello F, Pond GR, et al. Expression of EGFR, HER-2/neu and KIT in germ cell tumours. Clin Transl Oncol. 2010;12:443–9.CrossRefPubMed
24.
go back to reference Tsao M-S, Sakurada A, Cutz J-C, Zhu C-Q, Kamel-Reid S, Squire J, et al. Erlotinib in lung cancer—molecular and clinical predictors of outcome. N Engl J Med. 2005;353:133–44.CrossRefPubMed Tsao M-S, Sakurada A, Cutz J-C, Zhu C-Q, Kamel-Reid S, Squire J, et al. Erlotinib in lung cancer—molecular and clinical predictors of outcome. N Engl J Med. 2005;353:133–44.CrossRefPubMed
25.
go back to reference Centeno I, Blay P, Santamaría I, Astudillo A, Pitiot AS, Osorio FG, et al. Germ-line mutations in epidermal growth factor receptor (EGFR) are rare but may contribute to oncogenesis: a novel germ-line mutation in EGFR detected in a patient with lung adenocarcinoma. BMC Cancer. 2011;11:172.CrossRefPubMedPubMedCentral Centeno I, Blay P, Santamaría I, Astudillo A, Pitiot AS, Osorio FG, et al. Germ-line mutations in epidermal growth factor receptor (EGFR) are rare but may contribute to oncogenesis: a novel germ-line mutation in EGFR detected in a patient with lung adenocarcinoma. BMC Cancer. 2011;11:172.CrossRefPubMedPubMedCentral
26.
go back to reference Umar A, Boland CR, Terdiman JP, Syngal S, de la Chapelle A, Rüschoff J, et al. Revised Bethesda Guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability. J Natl Cancer Inst. 2004;96:261–8.CrossRefPubMedPubMedCentral Umar A, Boland CR, Terdiman JP, Syngal S, de la Chapelle A, Rüschoff J, et al. Revised Bethesda Guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability. J Natl Cancer Inst. 2004;96:261–8.CrossRefPubMedPubMedCentral
27.
go back to reference Moreira L, Muñoz J, Cuatrecasas M, Quintanilla I, Leoz ML, Carballal S, et al. Prevalence of somatic mutl homolog 1 promoter hypermethylation in Lynch syndrome colorectal cancer. Cancer. 2015;121:1395–404.CrossRefPubMed Moreira L, Muñoz J, Cuatrecasas M, Quintanilla I, Leoz ML, Carballal S, et al. Prevalence of somatic mutl homolog 1 promoter hypermethylation in Lynch syndrome colorectal cancer. Cancer. 2015;121:1395–404.CrossRefPubMed
28.
go back to reference Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer. 1981;47:207–14.CrossRefPubMed Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer. 1981;47:207–14.CrossRefPubMed
29.
go back to reference de Wit R, Fizazi K. Controversies in the management of clinical stage I testis cancer. J Clin Oncol. 2006;24:5482–92.CrossRefPubMed de Wit R, Fizazi K. Controversies in the management of clinical stage I testis cancer. J Clin Oncol. 2006;24:5482–92.CrossRefPubMed
30.
go back to reference Beyer J, Albers P, Altena R, Aparicio J, Bokemeyer C, Busch J, et al. Maintaining success, reducing treatment burden, focusing on survivorship: highlights from the third European consensus conference on diagnosis and treatment of germ-cell cancer. Ann Oncol. 2013;24:878–88.CrossRefPubMed Beyer J, Albers P, Altena R, Aparicio J, Bokemeyer C, Busch J, et al. Maintaining success, reducing treatment burden, focusing on survivorship: highlights from the third European consensus conference on diagnosis and treatment of germ-cell cancer. Ann Oncol. 2013;24:878–88.CrossRefPubMed
31.
go back to reference Hoskin P, Dilly S, Easton D, Horwich A, Hendry W, Peckham MJ. Prognostic factors in stage I non-seminomatous germ-cell testicular tumors managed by orchiectomy and surveillance: implications for adjuvant chemotherapy. J Clin Oncol. 1986;4:1031–6.CrossRefPubMed Hoskin P, Dilly S, Easton D, Horwich A, Hendry W, Peckham MJ. Prognostic factors in stage I non-seminomatous germ-cell testicular tumors managed by orchiectomy and surveillance: implications for adjuvant chemotherapy. J Clin Oncol. 1986;4:1031–6.CrossRefPubMed
32.
go back to reference Velasco A, Riquelme E, Schultz M, Wistuba II, Villarroel L, Pizarro J, et al. Mismatch repair gene expression and genetic instability in testicular germ cell tumor. Cancer Biol Ther. 2004;3:977–82.CrossRefPubMed Velasco A, Riquelme E, Schultz M, Wistuba II, Villarroel L, Pizarro J, et al. Mismatch repair gene expression and genetic instability in testicular germ cell tumor. Cancer Biol Ther. 2004;3:977–82.CrossRefPubMed
33.
go back to reference Olasz J, Mándoky L, Géczi L, Bodrogi I, Csuka O, Bak M. Influence of hMLH1 methylation, mismatch repair deficiency and microsatellite instability on chemoresistance of testicular germ-cell tumors. Anticancer Res. 2005;25:4319–24.PubMed Olasz J, Mándoky L, Géczi L, Bodrogi I, Csuka O, Bak M. Influence of hMLH1 methylation, mismatch repair deficiency and microsatellite instability on chemoresistance of testicular germ-cell tumors. Anticancer Res. 2005;25:4319–24.PubMed
34.
go back to reference Koul S, Houldsworth J, Mansukhani MM, Donadio A, McKiernan JM, Reuter VE, et al. Characteristic promoter hypermethylation signatures in male germ cell tumors. Mol Cancer. 2002;1:8.CrossRefPubMedPubMedCentral Koul S, Houldsworth J, Mansukhani MM, Donadio A, McKiernan JM, Reuter VE, et al. Characteristic promoter hypermethylation signatures in male germ cell tumors. Mol Cancer. 2002;1:8.CrossRefPubMedPubMedCentral
35.
go back to reference Hirsch FR, Varella-Garcia M, Bunn PAJ, Di Maria MV, Veve R, Bremmes RM, et al. Epidermal growth factor receptor in non-small-cell lung carcinomas: correlation between gene copy number and protein expression and impact on prognosis. J Clin Oncol. 2003;21:3798–807.CrossRefPubMed Hirsch FR, Varella-Garcia M, Bunn PAJ, Di Maria MV, Veve R, Bremmes RM, et al. Epidermal growth factor receptor in non-small-cell lung carcinomas: correlation between gene copy number and protein expression and impact on prognosis. J Clin Oncol. 2003;21:3798–807.CrossRefPubMed
36.
go back to reference Miyai K, Yamamoto S, Asano T, Tamai S, Matsubara O, Tsuda H. Protein overexpression and gene amplification of epidermal growth factor receptor in adult testicular germ cell tumors: potential role in tumor progression. Cancer Sci. 2010;101:1970–6.CrossRefPubMed Miyai K, Yamamoto S, Asano T, Tamai S, Matsubara O, Tsuda H. Protein overexpression and gene amplification of epidermal growth factor receptor in adult testicular germ cell tumors: potential role in tumor progression. Cancer Sci. 2010;101:1970–6.CrossRefPubMed
Metadata
Title
Epidermal growth factor receptor and epididymis invasion as prognostic biomarkers in clinical stage I testicular germ cell tumours
Authors
Miguel F. Sanmamed
E. Esteban
E. Uriol
R. Zarate
M. Capelan
C. Muriel
G. Crespo
J. P. Berros
P. Pardo-Coto
Q. Perez
C. Alvarez-Fernández
P. Jiménez Fonseca
M. Luque
A. Astudillo
Publication date
01-12-2017
Publisher
BioMed Central
Published in
Journal of Translational Medicine / Issue 1/2017
Electronic ISSN: 1479-5876
DOI
https://doi.org/10.1186/s12967-017-1162-3

Other articles of this Issue 1/2017

Journal of Translational Medicine 1/2017 Go to the issue